We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    ALZ-101
Previous Study | Return to List | Next Study

A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05328115
Recruitment Status : Recruiting
First Posted : April 14, 2022
Last Update Posted : June 13, 2022
Sponsor:
Collaborator:
CRST Oy
Information provided by (Responsible Party):
Alzinova AB

Brief Summary:
The main purpose of this study is to evaluate safety, tolerability and immunogenicity of the vaccine ALZ-101 against Alzheimer's Disease. Patients diagnosed with early Alzheimer's disease are randomised into two arms of active treatment and one of placebo. Patients are given four doses during 5 months and then followed up for 13 months.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Biological: ALZ-101 Other: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Parallel-group Multiple Dose Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
Actual Study Start Date : September 30, 2021
Estimated Primary Completion Date : July 31, 2023
Estimated Study Completion Date : July 31, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: ALZ-101 125 μg
Intra muscular injection of 125 μg of ALZ-101 adjuvanted vaccine dosed once a month at four doses
Biological: ALZ-101
Intramuscular injections of adjuvanted peptide vaccine against oligomeric Amyloid Beta.

Active Comparator: ALZ-101 250 μg
Intra muscular injection of 250 μg of ALZ-101 adjuvanted vaccine dosed once a month at four doses
Biological: ALZ-101
Intramuscular injections of adjuvanted peptide vaccine against oligomeric Amyloid Beta.

Placebo Comparator: Placebo
Saline solution mixed adjuvant and dosed once a month at four doses
Other: Placebo
Intramuscular injections of adjuvanted placebo.




Primary Outcome Measures :
  1. Number of adverse events (AEs) and serious AEs (SAEs) [ Time Frame: From enrolment through study completion, an average 1 year ]
    Any adverse or serious adverse events that could be associated with the study procedure.

  2. Number of participants with treatment-emergent AEs and SAEs [ Time Frame: From enrolment through study completion, an average 1 year ]
    Any adverse or serious adverse events that could be associated with the treatment.

  3. Number of AEs of special interest (AESIs), including injection-related events (IREs)and amyloid-related imaging abnormalities (ARIAs) [ Time Frame: From enrolment through study completion, an average 1 year ]
    Any adverse or adverse events of special interest that could be associated with the treatment.

  4. Number of participants with clinically significant cognitive or functional worsening of Alzheimer's Disease(AD) according to Alzheimer's DiseaseCooperative Study -Clinician's Global Impression of Change (ADCS-CGIC)scores of 6 and 7 [ Time Frame: From first dose to study completion, an average 1 year ]
    Any clinically significant worsening of cognitive functions as assessed by Alzheimer's DiseaseCooperative Study -Clinician's Global Impression of Change [ADCS-CGIC]scores. Scores are graded from 1 to 7, where 1 means very much improved cognitive function and 7 very much worsening cognitive function.


Secondary Outcome Measures :
  1. Aβ-specific antibody titre [ Time Frame: From first dose to study completion, an average 1 year ]
    Aβ-specific antibody titre of post-baseline samples (if baseline sample is negative) OR titre fold increase defined as the ratio of any post-baseline Aβ-specific antibody titre to baseline antibody titre in serum

  2. Number of titre-based responders [ Time Frame: From first dose to study completion, an average 1 year ]
    Number of titre-based responders, defined as post-baseline sample becoming positive for Aβ-specific antibodies(if baseline sample is negative) OR post-baseline titre at least four times the baseline antibody titre in serum

  3. Area under serum Aβ-specific antibody titre curve (AUC) [ Time Frame: From first dose to week 20 ]
    Area under serum Aβ-specific antibody titre curve (AUC) from Week 0 to Week 20.

  4. Maximum titre level (Cmax) [ Time Frame: From first dose to week 20 ]
    Plasma concentration of Aβ-specific antibodies at their maximum titre level.

  5. Time to Cmax(tmax) [ Time Frame: From first dose to week 20 ]
    Time to maximum titre levels of plasma Aβ-specific antibodies.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female subjects between 50 and 80 years(inclusive) of age at the time of informed consent
  2. Subjects capable of providing valid independent informed consent and signing the informed consent form (the subjects' capacity to provide valid consent should be determined in accordance with applicable professional standards, and will be based on the Investigator's judgement)
  3. Subjects with mild cognitive impairment(MCI) due to AD or mild AD according to National Institute of Aging -Alzheimer's Association (NIA-AA) core clinical criteria; subjects must have all of the following at screening:

    1. Clinical dementia rating(CDR) global score(GS) of 0.5 or 1
    2. CDR memory score of ≥0.5c. Mini mental state examination(MMSE) score of ≥20 points
  4. Screening cerebro-spinal fluid (CSF) results showing a pattern consistent with amyloid plaque load and indicative of AD pathology. The CSF results will be evaluated by the Investigator and will take into account the Aβ42/40ratio (cut-off level set by the laboratory)
  5. If the subject is receiving an acetylcholine esterase inhibitor (AChEI)or memantine or both for the treatment of MCI or AD, this treatment must be on a stable dosage for at least 8 weeks prior to the first dosing of investigational medicinal product(IMP). Treatment-naïve subjects may also be entered into the study
  6. Subjects must have an identified, reliable and knowledgeable study partner who is willing and able to support the participant and to provide follow-up information on the study participant throughout the course of the study. This person must, in the opinion of the Investigator, spend sufficient time with the study participant on a regular basis such that he or she can reliably fulfil the requirements of being a study partner (however, a study partner does not need to be living in the same household with the study participant)

Exclusion Criteria:

  1. Subjects having any contraindication to MRI scanning; or are unable to undergo brain MRI scanning according to the standard criteria of the MRI unit;or the Investigator believes that the subject will not be able to undergo further scans scheduled during the course of the study
  2. Screening MRI(3T)results showing evidence of clinically significant pathological lesions that could indicate a dementia-associated diagnosis other than early AD or cause a safety risk for the participant(a list of possible exclusionary findings is included in the main protocol text)
  3. Modified Hachinski Ischemia Score (mHIS) >4 at screening
  4. History of a cerebrovascular incident, including transient ischemic attack(TIA) or stroke, within 12 months of screening
  5. Subject with a history of seizures within 5 years of screening
  6. Any psychiatric diagnosis or symptoms (e.g.hallucinations, major depression, delusions, schizophrenia, bipolar disorder) that, in the opinion of the Investigator, could interfere with study procedures or assessments or participant safety. A subject with depression may, however, be included if treated with a stable dose of antidepressants for at least 8 weeks before screening and not fulfilling Diagnostic and Statistical Manual(DSM)-5 criteria for major depression at screening
  7. Significant risk of suicide (defined using the Columbia Suicide Severity Scale(C-SSRS), with the subject answering "yes" to suicidal ideation questions 4 or 5 or answering "yes" to suicidal behaviour) within 12 months of screening
  8. Disorder related to alcohol or drug abuse, as defined in DSM-5, within 5 years prior to screening
  9. Evidence of current or history of any significant autoimmune disease that, in the opinion of the Investigator, could interfere with evaluation of the study results or constitute a health hazard for the subject
  10. Evidence of an immune system that is compromised; including, but not limited to, a diagnosis of HIV(human immunodeficiency virus); or the subject has been splenectomised or has received an organ transplant (corneal transplants excluded), or is receiving chronic systemic immunosuppressive medication
  11. Evidence of current clinically significant and possibly unstable pulmonary, gastrointestinal, renal, hepatic, endocrine, hematological or cardiovascular system disease or metabolic disturbance
  12. Diagnosis of cancer (hematological or solid tumor) for which the subject is currently being treated, or for which there has been treatment within 5 years preceding screening, or for which there is still evidence of active disease. Subjects with local prostate cancer or local dermatological tumors, such as basal or squamous cell carcinoma, may be included
  13. Any clinically significant abnormalities in laboratory tests, vital signs, ECG or physical examination findings at screening that in the opinion of the Investigator require further investigation or treatment, or may interfere with study procedures or safety. These may include, but are not limited to, the following:

    1. estimated glomerular filtration ratio (eGFR) <30 ml/min/1.73m2, based on the Chronic Kidney Disease Epidemiology Collaboration(CKD-EPI) equation
    2. plasma total bilirubin value >2 times the upper limit of the reference range
    3. plasma alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) value >2 times the upper limit of the reference range
    4. low vitamin B12 or folate values that are considered to be clinically significant in relation to cognitive impairment. In such cases, re-screening is permissible after supplementation therapy has been provided for a sufficient time
    5. prolonged QT corrected for heart rate by Fridericia's cube root formula(QTcF) interval of >470 ms
  14. Clinically suspected active neuroborreliosis, confirmed by the presence of Borrelia antibodies in CSF
  15. Contraindication to lumbar puncture (LP). These contraindications may include, but are not limited to, the following:

    1. increased intracranial pressure (ICP)
    2. skin infection at the LP site
    3. significant lumbar spine deformity
    4. bleeding diathesis (e.g., significant thrombocytopenia)
    5. taking anticoagulant therapy (e.g., warfarin, dabigatran, apixaban, or other blood factor or thrombin inhibitor). Use of anti-platelet therapy(e.g. low-dose aspirin) may be permitted if deemed appropriate in the Investigator's judgement
  16. Current or anticipated use,or recent prior use (pre-study time limits specified in the main protocol text) of disallowed concomitant treatment
  17. Any vaccination within 2weeks prior to screening
  18. History of severe drug allergy (anaphylactic shock or drug-induced hypersensitivity syndrome), or known hypersensitivity to vaccines, including constituents of vaccines
  19. Having received in another clinical trial

    1. any therapeutic monoclonal antibody, protein derived from a monoclonal antibody or immunoglobulin therapy within 6 months before screening
    2. active anti-amyloid immunization or other active immunization for the treatment of AD
    3. any other investigational medication (unless it can be documented that the subject received only placebo) or device within 3 months or 5 half-lives(which ever is longer) before screening
  20. Any condition that may be contributing to cognitive impairment above and beyond that caused by the subject's early AD
  21. Disease or medication that, in the opinion of the Investigator, could interfere with the assessments of safety, tolerability or immunogenicity
  22. Planned surgery requiring general, spinal or epidural anaesthesia that would take place during the study. Planned surgery requiring only local anaesthesia need not result in exclusion, if in the opinion of the Investigator this operation does not interfere with study procedures and participant safety
  23. Female subjects of childbearing potential(defined in detail in the main protocol text)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05328115


Contacts
Layout table for location contacts
Contact: Stefan Pierrou, PhD +46708123615 Stefan.Pierrou@alzinova.com
Contact: Kristina Torfgård, PhD +46 708 467975 kristina.torfgard@alzinova.com

Locations
Layout table for location information
Finland
Clinical Research Services Turku -CRST Oy Recruiting
Turku, Finland, FI-20520
Contact: Juha Rinne, MD    +358 23131866    juha.rinne@crst.fi   
Contact: Zsofia Lovro, MD    +358 45 896 6565    zsofia.lovro@crst.fi   
Sponsors and Collaborators
Alzinova AB
CRST Oy
Investigators
Layout table for investigator information
Principal Investigator: Juha Rinne, MD CRST Oy
Layout table for additonal information
Responsible Party: Alzinova AB
ClinicalTrials.gov Identifier: NCT05328115    
Other Study ID Numbers: ALZ-C-001
2019-002277-62 ( EudraCT Number )
First Posted: April 14, 2022    Key Record Dates
Last Update Posted: June 13, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders